Compare Ascendis Pharma A/S (ASND) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Alibaba Group — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Alibaba Group trades at $112.78 (market cap $269.48B). The key difference: Alibaba Group is far larger — about 15.2× Ascendis Pharma A/S's market cap, and Alibaba Group pays a 0.93% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BABA | |
|---|---|---|
Market Cap | $17.74B | $269.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $189.34 |
52-Week Low | $163.32 | $94.83 |
Enterprise Value | $18.11B | $264.31B |
Volume | — | 18,069,938 |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Alibaba (BABA) trades at $112.33, up 1.07% today, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with improving fundamentals, including a 13.05% net margin and $130.11B net income for 2025. The stock faces headwinds from securities investigations but benefits from AI momentum and narrowing losses in quick commerce.
Outlook remains positive with an 86% buy rating and $195 consensus target, though risks include regulatory scrutiny and earnings volatility. Upside potential hinges on execution in cloud and e-commerce, while legal overhangs and macroeconomic pressures pose near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
